- Retatrutide (LY3437943) is an investigational triple agonist developed by Eli Lilly that simultaneously targets GLP-1, GIP, and glucagon receptors, making it the next generation beyond semaglutide and tirzepatide.
- Phase 2 trial data published in the New England Journal of Medicine showed an average 24.2% body weight loss at the highest dose over 48 weeks, the highest result ever reported in a pharmaceutical obesity trial.
- The addition of glucagon receptor activation is the key differentiator: it increases energy expenditure, mobilizes fat stores, and drives remarkable reductions in liver fat (89% reduction at the highest dose).
- Retatrutide is NOT FDA-approved. It is currently in Phase 3 trials under Eli Lilly's TRIUMPH program, with approval expected no earlier than 2026 to 2027.
- Semaglutide and tirzepatide remain the proven, available options today. Retatrutide represents the next frontier, and Kind MD will offer it to patients when it becomes available.
Retatrutide is an investigational drug and is not FDA-approved for any indication. It is not available by prescription and cannot be obtained through compounding. The data discussed in this article comes exclusively from Phase 2 clinical trials. Results may change as larger Phase 3 trials are completed. This article is for educational purposes only.
What is retatrutide?
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly that targets three receptors simultaneously: GLP-1, GIP, and glucagon. It represents the next generation beyond single agonists (semaglutide) and dual agonists (tirzepatide), and has produced the highest weight loss results ever recorded in a pharmaceutical clinical trial.
The story of GLP-1 medications is a story of escalating ambition. Researchers discovered that adding GIP receptor activation to GLP-1 activation, as tirzepatide does, produced meaningfully greater weight loss. The natural question followed: what happens if you add a third target?
Eli Lilly designed retatrutide to answer that question. The drug was engineered to activate three hormone receptor pathways simultaneously, each playing a distinct role in how the body manages weight, appetite, and metabolism. The Phase 2 data, published in the New England Journal of Medicine in 2023, suggested the answer was remarkable: average weight loss of 24.2% at the highest dose over 48 weeks, a number that had never been achieved with any pharmacological intervention before.[1]
To put that number in context: a person starting at 250 pounds on the highest dose of retatrutide lost an average of 60 pounds in less than a year. Many participants lost more. The results were striking enough that the research community took immediate notice, and Eli Lilly moved quickly into Phase 3 trials.
But there is a critical caveat that belongs in every conversation about retatrutide: it is not approved, not available, and we are still waiting on the larger, longer trials that will determine whether Phase 2 results hold at scale. The science is exciting. The drug is not yet here.
How does retatrutide work?
Retatrutide works through three distinct hormonal mechanisms. Understanding each one explains why the drug may produce greater weight loss than its predecessors, and why the glucagon component in particular is generating so much scientific interest.
Suppresses appetite by signaling fullness to the brain. Slows gastric emptying. Regulates blood sugar by stimulating insulin and suppressing glucagon. The foundation shared with semaglutide.
Enhances insulin sensitivity and amplifies the metabolic effects of GLP-1. Activating both GLP-1 and GIP together produces greater weight loss than either alone. The addition shared with tirzepatide.
Increases energy expenditure. Mobilizes fat stores for fuel. Promotes hepatic lipid oxidation, the process by which the liver burns stored fat. This third mechanism is what sets retatrutide apart.
The GLP-1 component: appetite and blood sugar
GLP-1 receptor activation is the foundation shared by all drugs in this class. It signals fullness to the hypothalamus in the brain, slows the rate at which the stomach empties after eating, and regulates blood sugar by stimulating insulin release and suppressing glucagon. This is how semaglutide works. Retatrutide includes this mechanism as one of three.
The GIP component: amplifying metabolic effect
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that regulates insulin secretion and fat storage. When activated alongside GLP-1 receptors, GIP signaling enhances insulin sensitivity and amplifies the weight loss effect beyond what GLP-1 activation alone can achieve. This is why tirzepatide outperforms semaglutide in head-to-head weight loss data. Retatrutide includes GIP activation as its second mechanism.
The glucagon component: the game-changer
This is where retatrutide breaks genuinely new ground. Glucagon is typically associated with raising blood sugar, which is why some initially questioned the wisdom of activating the glucagon receptor in an obesity drug. But researchers like Jonathan Day and colleagues had studied co-agonists targeting both GLP-1 and glucagon receptors for years, finding that glucagon receptor activation increases energy expenditure and mobilizes fat stores when GLP-1 is also activated simultaneously.[8]
In the context of a triple agonist, activating the glucagon receptor drives three important effects: it increases the calories the body burns at rest, it signals fat cells to release stored lipids for fuel, and it promotes hepatic lipid oxidation, essentially telling the liver to burn its stored fat. This last effect may explain the extraordinary reduction in liver fat content seen in Phase 2 data.
"The addition of glucagon receptor agonism to GLP-1 and GIP receptor agonism represents a rational strategy to increase energy expenditure while maintaining the metabolic benefits of incretin-based therapy."
A 2019 review in Molecular Metabolism mapped in detail how co-activation of these three receptor pathways interacts across the liver, fat tissue, brain, and gut, providing the theoretical framework that retatrutide's clinical results are now beginning to validate in humans.[13]
What does the research show?
The central evidence for retatrutide comes from a single Phase 2 randomized controlled trial published in the New England Journal of Medicine in July 2023. The results attracted immediate attention from obesity researchers worldwide.
The Phase 2 trial: Jastreboff et al., NEJM 2023
The trial enrolled 338 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity, but without type 2 diabetes. Participants were randomized to one of five retatrutide dose groups or placebo and treated for 48 weeks.[1]
The results across dose groups showed a clear dose-dependent response: at the 4mg dose, participants lost 8.7% of body weight; at 8mg, 22.8%; and at the highest 12mg dose, 24.2%. Every active dose group outperformed the placebo group, which lost only 2.1%. The trial authors noted that weight loss had not yet plateaued at 48 weeks in the higher-dose groups, suggesting final results at trial completion could be even higher.
For comparison, semaglutide produced 14.9% weight loss over 68 weeks in the STEP 1 trial. Tirzepatide produced 22.5% weight loss over 72 weeks in SURMOUNT-1. Retatrutide achieved 24.2% in 48 weeks. The trajectory is unmistakable.
The liver fat finding
Perhaps the most striking secondary finding in the Phase 2 trial was the effect on liver fat. At the highest dose, participants showed an 89% reduction in liver fat content as measured by MRI. Researchers Sanyal and colleagues commenting in the same NEJM issue called this result "unprecedented" for a single pharmacological intervention.[12] For context, semaglutide and tirzepatide both reduce liver fat, but not at this magnitude. This finding has significant implications for the treatment of MASLD (metabolic dysfunction-associated steatotic liver disease), which affects an estimated 25% of the global population.
The type 2 diabetes trial
A parallel Phase 2 trial published in The Lancet in 2023 tested retatrutide in 281 adults with type 2 diabetes. At the highest dose, participants lost an average of 16.9% of body weight over 36 weeks, while also achieving substantial reductions in HbA1c (a key marker of blood sugar control).[2] These results position retatrutide as a potential treatment for both obesity and type 2 diabetes, similar to the pathway semaglutide and tirzepatide have already traveled.
Retatrutide vs. semaglutide vs. tirzepatide
The clearest way to understand where retatrutide fits is to compare the three generations side by side. Each represents a step forward in targeting more hormonal pathways simultaneously.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Type | Single agonist | Dual agonist | Triple agonist |
| Targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Best weight loss (trial) | 14.9% (STEP 1) | 22.5% (SURMOUNT-1) | 24.2% (Phase 2) |
| Duration of data | 68 weeks | 72 weeks | 48 weeks (Phase 2 only) |
| CV outcomes data | Yes (SELECT: 20% reduction) | Pending | No |
| FDA approved | Yes | Yes | No (Phase 3 ongoing) |
| Available for Rx | Yes | Yes | No |
| Manufacturer | Novo Nordisk | Eli Lilly | Eli Lilly |
| Liver fat reduction | Modest | Moderate | 89% at highest dose (Phase 2) |
| Dosing | Weekly injection | Weekly injection | Weekly injection |
One important note on interpreting this table: retatrutide's weight loss data comes from a 48-week Phase 2 trial with 338 participants. Semaglutide and tirzepatide have data from Phase 3 trials with thousands of participants and longer follow-up periods. Phase 2 results do not always replicate perfectly in larger trials. The retatrutide numbers are genuinely remarkable, but they should be read as early signal rather than final proof.
Interested in starting GLP-1 treatment today while the next generation is in trials?
Semaglutide and tirzepatide are available now. Take our free 2-minute quiz to see which is right for you.
Take the Free Quiz →When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. Phase 3 is the final stage of clinical testing before a company can apply for FDA approval. These trials involve thousands of participants across multiple sites and are designed to confirm safety and efficacy at scale.[11]
The realistic timeline for FDA approval is 2026 at the earliest, with 2027 being a more conservative estimate. This depends on when Phase 3 data becomes available, how long FDA review takes, and whether any unexpected safety signals emerge at larger scale. Eli Lilly has not confirmed a specific submission or approval timeline.
For patients asking whether they can access retatrutide now, the answer is straightforward: no. The only legal way to access retatrutide today is through an authorized clinical trial. It cannot be prescribed outside of trials, and it cannot be compounded since compounding is only available for FDA-approved drugs in documented shortage. Any source claiming to offer retatrutide outside of a clinical trial should be treated with serious skepticism.
Kind MD is following the TRIUMPH trial program closely. When retatrutide receives FDA approval, we will evaluate it alongside our existing formulary and offer it to patients when appropriate.
Potential benefits beyond weight loss
One of the most compelling aspects of retatrutide's early data is the range of metabolic benefits it appears to produce beyond weight reduction. Several of these secondary findings have significant clinical implications for common conditions.
Fatty liver disease (MASLD/NAFLD)
The 89% reduction in liver fat content observed in Phase 2 at the highest dose is exceptional. MASLD affects an estimated 25 to 30% of adults worldwide and is one of the leading causes of liver-related illness and disease progression. Current treatment options are limited; lifestyle changes produce modest results for most patients. The glucagon receptor component of retatrutide is believed to be central to its liver effect, as glucagon receptor activation promotes hepatic lipid oxidation, the biochemical process by which liver cells break down and clear stored fat.[12] Dedicated trials in MASLD are expected as part of retatrutide's Phase 3 program.
Metabolic syndrome
Metabolic syndrome is a cluster of conditions including abdominal obesity, high blood pressure, elevated blood sugar, and abnormal cholesterol. Phase 2 data showed retatrutide participants experienced improvements across multiple markers of metabolic health simultaneously. Given the multi-receptor mechanism, this is mechanistically expected: GLP-1 receptor activation improves blood sugar, GIP receptor activation improves insulin sensitivity, and glucagon receptor activation reduces visceral fat and improves lipid metabolism.
Cardiovascular effects
Semaglutide's SELECT trial demonstrated a 20% reduction in major cardiovascular events in high-risk patients.[5] Retatrutide has no comparable cardiovascular outcomes data yet. Phase 3 trials typically include cardiovascular endpoints for drugs in this class, and it is likely that retatrutide's Phase 3 program will include or eventually lead to a dedicated cardiovascular outcomes trial. Whether the triple agonist mechanism confers cardiovascular benefits beyond those already demonstrated by semaglutide remains an open question that research will answer over the coming years.
Side effects in clinical trials
The side effect profile observed in Phase 2 was broadly similar to other GLP-1 medications, though with some dose-dependent differences that Phase 3 data will clarify at larger scale.
The most common adverse events were gastrointestinal:
- Nausea: Reported by approximately 25% of participants at lower doses, increasing to around 45% at the highest 12mg dose. This is consistent with, though slightly higher than, what is typically seen with semaglutide and tirzepatide. Onset was most common in the first eight weeks and generally decreased over time with dose stabilization.
- Diarrhea: Reported in 20 to 30% of participants at higher doses. Dose-dependent and most common during dose escalation periods.
- Vomiting: Reported in 10 to 20% of participants at higher doses. Generally mild to moderate in severity.
- Constipation: Reported in approximately 15% of participants. Consistent with slowed gastric emptying common to all GLP-1 class drugs.
- Decreased appetite: The intended mechanism, but notable as a reported effect worth monitoring to ensure adequate nutrition.
- Heart rate increase: A modest increase in resting heart rate was observed, similar to what has been seen with other drugs in this class. The clinical significance of this finding in larger, longer trials is not yet established.
Treatment discontinuations due to adverse events were more common at the highest doses than at lower doses, which is a typical dose-response pattern. Most discontinuations were due to gastrointestinal events. Phase 3 trials with larger populations and longer follow-up periods will provide a more complete picture of retatrutide's long-term safety profile, including any rare events that would not be detected in a 338-person Phase 2 trial.
The side effect profile seen in Phase 2 does not suggest anything qualitatively different from existing GLP-1 medications in terms of safety class, but the quantity of comprehensive safety data for retatrutide remains significantly smaller than what exists for approved drugs. This is a normal feature of the drug development process, not a specific concern, and it is exactly why Phase 3 trials exist.
What this means for GLP-1 treatment today
Retatrutide is part of a clear and accelerating pattern in obesity pharmacology: each generation of medications targets more receptor pathways simultaneously and produces greater weight loss. Single agonists gave way to dual agonists. Dual agonists are now giving way to triple agonists. The science is moving fast.
But the right frame for patients thinking about their own treatment is not to wait for the next thing. Semaglutide and tirzepatide are proven, available, and extraordinarily effective by any historical standard. Tirzepatide's 22.5% average weight loss was considered remarkable when SURMOUNT-1 published in 2022. For patients who need treatment now, these are the right tools, and the data behind them is deep and well-established.
What retatrutide tells us is that the ceiling may not have been reached yet. The addition of glucagon receptor activation appears to unlock a meaningful additional degree of weight loss and metabolic benefit. For patients with fatty liver disease in particular, the liver fat data from Phase 2 is the most promising pharmacological result ever reported for that condition.
At Kind MD, we are tracking retatrutide's Phase 3 program and will evaluate it for our formulary as data matures and FDA review proceeds. Our commitment is to give patients access to the best available evidence-based treatments. Right now, that means semaglutide and tirzepatide. In the years ahead, it may well include retatrutide alongside them.
